Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Encysive Pharmaceuticals (ENCY) -- Ignore unavailable to you. Want to Upgrade?

To: idos who wrote (158)	12/15/2006 2:48:41 PM
From: tuck	Respond to of 205

>>Encysive Pharmaceuticals' THELIN (sitaxentan sodium) Receives Positive Opinion From Australian Health Authority Friday December 15, 1:47 pm ET HOUSTON, Dec. 15, 2006 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals (NASDAQ:ENCY - News) today announced that the Australian Drug Evaluation Committee (ADEC) of the Therapeutic Goods Administration (TGA) issued a positive opinion recommending the approval of THELIN(tm) (sitaxentan1 sodium) 100 mg tablets as a once daily oral treatment for patients with pulmonary arterial hypertension (PAH). The TGA will now consider the ADEC's positive opinion in making its decision regarding marketing approval for THELIN(tm).<< No such luck on the fill, but at least the original position is looking better. Cheers, Tuck